AKTX
Akari Therapeutics Plc · Healthcare · Market cap $1.45T
Akari Therapeutics Plc (AKTX) has 13 SEC Form 4 filings (32 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Oct 16, 2026.
- Industry:Biotechnology
- CEO:Abizer Gaslightwala
- Employees:6
- HQ:Tampa, FL, US
- IPO:2014-01-06
No open-market insider trades for AKTX (Akari Therapeutics Plc) in the last 365 days.
Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.
Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does AKTX have?
Akari Therapeutics Plc (AKTX) has 13 SEC Form 4 filings (32 transaction rows) in the rolling 365-day window, disclosed by 0 distinct insiders. Most recent filing: Oct 16, 2026.
When was the most recent SEC Form 4 filing for AKTX?
The most recent Form 4 filing for AKTX on Tracefour is dated Oct 16, 2026.
Can I get alerts for AKTX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Akari Therapeutics Plc (AKTX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Akari Therapeutics Plc is in the Healthcare sector.